In Brief: VidaMed
This article was originally published in The Gray Sheet
Executive Summary
VidaMed: Board of directors seeking replacement for Stuart Edwards, current CEO, president and founder of the Menlo Park, California-based firm. A committee including three top-level VidaMed execs -- Chairman David Douglass and board members Pierre Lamond and Lawrence Mohr -- is conducting a search for a successor to Edwards, who will remain a member of the firm's board of directors. VidaMed says it is making the change in preparation for premarket approval of its TUNA transurethral needle ablation radiofrequency system for treatment of benign prostatic hyperplasia, which the firm expects to receive in 1996...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.